Naren Ramakrishna
Radiation Oncology · Orlando, FLNPI 1194781377
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $881 of the $1,324 with a category attached, or 66.5%. Brainlab, Inc. accounts for 89.9% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2019 at $666 and has fallen 91.9% since, to $54 in 2025.
Across 15 payments — averaging $88.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Brainlab, Inc.$1K
- Mevion_medical_systems_inc$46
- Boston Scientific$38
- Novocure Inc.$32
- Varian Medical Systems, Inc.$18
Across 37 payments — averaging $2048.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novocure Inc.$76K
What the payments were for
- Travel & lodging$88167%
- Food & beverage$43333%
- Gifts$101%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Brainlab, Inc. | 8 | $1,190 |
| Mevion_medical_systems_inc | 3 | $46 |
| Boston Scientific | 2 | $38 |
| Novocure Inc. | 1 | $32 |
| Varian Medical Systems, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,324 in reported general payments places this provider in the 60th percentile of 465 radiation oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Memantine Hcl | 78 | $740 |
| Dexamethasone | 67 | $551 |
| Levetiracetam | 22 | $194 |
| Lorazepam | 23 | $18 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Orlando
- Shravan KandulaOrlando$444K
- Ravi ShridharOrlando$192K
- Akash NandaOrlando$165K
- Imran MohiuddinOrlando$93K
- Charles HodgeOrlando$34K
- Bridget KoontzOrlando$26K
- Justin RineerOrlando$11K
- Matthew BiagioliOrlando$10K
- Shiv DesaiOrlando$8K
- Nina JohnsonOrlando$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.